Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin
50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of
corresponding doses of sitagliptin and China-sourced metformin as individual tablets will be
bioequivalent based on assessment of the AUC(0-t) and Cmax, for both sitagliptin and
metformin.